GSK to nearly double cancer medicines in trials next year

· Health · United Kingdom

UK drugmaker GSK plans to nearly double the number of cancer medicines in clinical trials next year. The move signals a deeper push into oncology as the company seeks new growth drivers.

Why it matters：A larger oncology pipeline matters for patients awaiting new treatments and for GSK's ability to compete with rivals in the lucrative cancer market.

Key points

  • GSK aims to nearly double cancer medicines in trials next year.
  • The push deepens its oncology focus.

Sources (original reporting)

More stories from this day